‘Unmerited’ hep C patent contributes to Gilead monopoly, says NGO
The European Patent Office has upheld protection relating to Gilead’s costly Hepatitis C drug Sovaldi, which Médecins du Monde claims prevents patients from receiving affordable treatment.